Literature DB >> 19576239

Expression of Hsp90 chaperone [corrected] proteins in human tumor tissue.

Christina L McDowell1, R Bryan Sutton, Wolfgang M J Obermann.   

Abstract

The activity of many oncogenic proteins depends on the molecular chaperone Hsp90. Recent studies indicate that tumorigenesis is associated with increased expression of chaperones, such as Hsp90. However, little is known about the isoform dependence and cochaperone contribution on tumor formation. Here we report the first systematic expression profiling for Hsp90alpha and Hsp90beta, the cochaperones Aha1, Cdc37, p23, Tpr2, and the Hsp90 dependent transcription factor HSF1 in a set of different tumor tissue samples. We find that in 10 out of 17 human tumors the expression level of at least one Hsp90 or Hsp90 cochaperone protein is significantly elevated. However, individual tumors show unique patterns of expression. Furthermore, Hsp90alpha and Hsp90beta expression levels are not related. Our results suggest that expression profiling of Hsp90alpha and Hsp90beta and its cochaperone proteins may be useful for cancer diagnosis and prognosis as well as for tailoring of drugs that interfere with the Hsp90 system in a tumor specific manner.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19576239     DOI: 10.1016/j.ijbiomac.2009.06.012

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  24 in total

Review 1.  Macrocyclic inhibitors of hsp90.

Authors:  Victoria A Johnson; Erinprit K Singh; Lidia A Nazarova; Leslie D Alexander; Shelli R McAlpine
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

Review 2.  HSP90AB1: Helping the good and the bad.

Authors:  Michael Haase; Guido Fitze
Journal:  Gene       Date:  2015-09-07       Impact factor: 3.688

3.  Hsp90 cochaperone Aha1 is a negative regulator of the Saccharomyces MAL activator and acts early in the chaperone activation pathway.

Authors:  Fulai Ran; Nidhi Gadura; Corinne A Michels
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

4.  Identification and verification of Hsp90-beta as a potential serum biomarker for lung cancer.

Authors:  Biaoxue Rong; Chongchong Zhao; Hua Liu; Zongjuan Ming; Xiguang Cai; Wenlong Gao; Shuanying Yang
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

Review 5.  Selective targeting of the stress chaperome as a therapeutic strategy.

Authors:  Tony Taldone; Stefan O Ochiana; Pallav D Patel; Gabriela Chiosis
Journal:  Trends Pharmacol Sci       Date:  2014-09-25       Impact factor: 14.819

6.  Increased level of Hsp90-beta in bronchoalveolar lavage fluid correlates with lymphatic invasion and advanced stage of lung cancer patients.

Authors:  Biaoxue Rong; Xiguang Cai; Hua Liu; Tian Fu; Wenlong Gao; Chongchong Zhao; Yurong Lin
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

7.  Mutation of essential Hsp90 co-chaperones SGT1 or CNS1 renders yeast hypersensitive to overexpression of other co-chaperones.

Authors:  Jill L Johnson; Abbey D Zuehlke; Victoria R Tenge; Jordan C Langworthy
Journal:  Curr Genet       Date:  2014-06-13       Impact factor: 3.886

Review 8.  HSP90 manages the ends.

Authors:  Diane C DeZwaan; Brian C Freeman
Journal:  Trends Biochem Sci       Date:  2010-03-16       Impact factor: 13.807

Review 9.  Targeting the dynamic HSP90 complex in cancer.

Authors:  Jane Trepel; Mehdi Mollapour; Giuseppe Giaccone; Len Neckers
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

Review 10.  Hsp90, an unlikely ally in the war on cancer.

Authors:  Jared J Barrott; Timothy A J Haystead
Journal:  FEBS J       Date:  2013-02-24       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.